290 related articles for article (PubMed ID: 32007664)
1. Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.
Evans LW; Bender A; Burnett L; Godoy L; Shen Y; Staten D; Zhou T; Angermann JE; Ferguson BS
J Nutr Biochem; 2020 May; 79():108339. PubMed ID: 32007664
[TBL] [Abstract][Full Text] [Related]
2. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A
Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent Effects of PRC2 and HDAC Inhibitors on Cardiomyocyte Hypertrophy Induced by Phenylephrine.
Zhao Z; Lv J; Guo N; Guo Q; Zeng S; Fang Y; Chen W; Wang Z
Curr Drug Targets; 2023; 24(4):371-378. PubMed ID: 36734909
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II induces cardiomyocyte hypertrophy probably through histone deacetylases.
Lu Y; Yang S
Tohoku J Exp Med; 2009 Sep; 219(1):17-23. PubMed ID: 19713680
[TBL] [Abstract][Full Text] [Related]
5. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
[TBL] [Abstract][Full Text] [Related]
6. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression.
Morales CR; Li DL; Pedrozo Z; May HI; Jiang N; Kyrychenko V; Cho GW; Kim SY; Wang ZV; Rotter D; Rothermel BA; Schneider JW; Lavandero S; Gillette TG; Hill JA
Sci Signal; 2016 Apr; 9(422):ra34. PubMed ID: 27048565
[TBL] [Abstract][Full Text] [Related]
8. Pan-histone deacetylase inhibitors regulate signaling pathways involved in proliferative and pro-inflammatory mechanisms in H9c2 cells.
Majumdar G; Adris P; Bhargava N; Chen H; Raghow R
BMC Genomics; 2012 Dec; 13():709. PubMed ID: 23249388
[TBL] [Abstract][Full Text] [Related]
9. A machine learning-driven study indicates emodin improves cardiac hypertrophy by modulation of mitochondrial SIRT3 signaling.
Gao J; Zhang K; Wang Y; Guo R; Liu H; Jia C; Sun X; Wu C; Wang W; Du J; Chen J
Pharmacol Res; 2020 May; 155():104739. PubMed ID: 32135248
[TBL] [Abstract][Full Text] [Related]
10. DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.
Okabe K; Matsushima S; Ikeda S; Ikeda M; Ishikita A; Tadokoro T; Enzan N; Yamamoto T; Sada M; Deguchi H; Shinohara K; Ide T; Tsutsui H
Hypertension; 2020 Apr; 75(4):991-1001. PubMed ID: 32160098
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding.
Kee HJ; Sohn IS; Nam KI; Park JE; Qian YR; Yin Z; Ahn Y; Jeong MH; Bang YJ; Kim N; Kim JK; Kim KK; Epstein JA; Kook H
Circulation; 2006 Jan; 113(1):51-9. PubMed ID: 16380549
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.
Kang SH; Seok YM; Song MJ; Lee HA; Kurz T; Kim I
Mol Pharmacol; 2015 May; 87(5):782-91. PubMed ID: 25667225
[TBL] [Abstract][Full Text] [Related]
13. Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.
Schuetze KB; Stratton MS; Blakeslee WW; Wempe MF; Wagner FF; Holson EB; Kuo YM; Andrews AJ; Gilbert TM; Hooker JM; McKinsey TA
J Pharmacol Exp Ther; 2017 Apr; 361(1):140-150. PubMed ID: 28174211
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Histone Deacetylases Induces K+ Channel Remodeling and Action Potential Prolongation in HL-1 Atrial Cardiomyocytes.
Lugenbiel P; Govorov K; Rahm AK; Wieder T; Gramlich D; Syren P; Weiberg N; Seyler C; Katus HA; Thomas D
Cell Physiol Biochem; 2018; 49(1):65-77. PubMed ID: 30134221
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of C/EBPβ and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA-induced hypertrophy.
Lee E; Lee HA; Kim M; Do GY; Cho HM; Kim GJ; Jung H; Song JH; Cho JM; Kim I
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):226-236. PubMed ID: 30099761
[TBL] [Abstract][Full Text] [Related]
16. Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.
Xu Q; Patel D; Zhang X; Veenstra RD
Am J Physiol Heart Circ Physiol; 2016 Nov; 311(5):H1139-H1149. PubMed ID: 27638876
[TBL] [Abstract][Full Text] [Related]
17. Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes.
Alcendor RR; Kirshenbaum LA; Imai S; Vatner SF; Sadoshima J
Circ Res; 2004 Nov; 95(10):971-80. PubMed ID: 15486319
[TBL] [Abstract][Full Text] [Related]
18. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition.
Zhang LX; Zhao Y; Cheng G; Guo TL; Chin YE; Liu PY; Zhao TC
Am J Physiol Heart Circ Physiol; 2010 Jun; 298(6):H2154-63. PubMed ID: 20382965
[TBL] [Abstract][Full Text] [Related]
19. Divergent and Overlapping Roles for Selected Phytochemicals in the Regulation of Pathological Cardiac Hypertrophy.
Evans L; Shen Y; Bender A; Burnett LE; Li M; Habibian JS; Zhou T; Ferguson BS
Molecules; 2021 Feb; 26(5):. PubMed ID: 33668293
[TBL] [Abstract][Full Text] [Related]
20. Sodium butyrate attenuates angiotensin II-induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6-dependent mechanism.
Zhang L; Deng M; Lu A; Chen Y; Chen Y; Wu C; Tan Z; Boini KM; Yang T; Zhu Q; Wang L
J Cell Mol Med; 2019 Dec; 23(12):8139-8150. PubMed ID: 31565858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
